Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion type Assertion NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_head.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion description "[The HER2-positive and HER2-negative GC cell lines were treated with trastuzumab, gastrin, or their combination in vitro and in xenograft model.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_provenance.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion evidence source_evidence_literature NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_provenance.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion SIO_000772 26173505 NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_provenance.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion wasDerivedFrom befree-2016 NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_provenance.
- NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_assertion wasGeneratedBy ECO_0000203 NP1290081.RAxlEY6owG5O7QrZNW9c4xwWOWfACcYTZ3tvUC4Gls-iE130_provenance.